NCT03510871: Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 2 | 43 | RoW | nivolumab, ipilimumab, nivolumab plus ipilimumab | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, National Cheng-Kung University Hospital, China Medical University Hospital, Chang Gung Memorial Hospital, Mackay Memorial Hospital, Tri-Service General Hospital | Hepatocellular Carcinoma (HCC) | 05/24 | 05/24 | | |
